Table 2 List of compounds and targets that are currently in clinical development
From: Neutrophils in cancer: prognostic role and therapeutic strategies
Drug | Mechanism of action | Study number | Clinical stage | Indication | Alone or in combination |
|---|---|---|---|---|---|
Reparixin | Reparixin Noncompetitive allosteric inhibitor of CXCR1 and CXCR2 chemokine. | NCT02001974 | I | Metastatic Breast Cancer | Paclitaxel + Reparixin |
Reparixin | Reparixin Noncompetitive allosteric inhibitor of CXCR1 and CXCR2 chemokine | NCT01861054 | II | Metastatic Breast Cancer | Alone |
Reparixin | Reparixin Noncompetitive allosteric inhibitor of CXCR1 and CXCR2 chemokine | NCT02370238 | II | Metastatic Breast Cancer | Paclitaxel in Combination With Reparixin or Placebo |